Last updated: 15 May 2024 at 7:09am EST

Jon Stonehouse Net Worth




The estimated Net Worth of Jon P Stonehouse is at least $11.2 Millón dollars as of 13 May 2024. Mr. Stonehouse owns over 30,000 units of Biocryst Pharmaceuticals stock worth over $8,717,662 and over the last 18 years he sold BCRX stock worth over $166,696. In addition, he makes $2,284,300 as President, Chief Executive Officer y Director at Biocryst Pharmaceuticals.

Mr. Stonehouse BCRX stock SEC Form 4 insiders trading

Jon has made over 32 trades of the Biocryst Pharmaceuticals stock since 2007, according to the Form 4 filled with the SEC. Most recently he bought 30,000 units of BCRX stock worth $166,500 on 13 May 2024.

The largest trade he's ever made was exercising 297,573 units of Biocryst Pharmaceuticals stock on 1 December 2022 worth over $422,554. On average, Jon trades about 19,218 units every 70 days since 2007. As of 13 May 2024 he still owns at least 1,127,770 units of Biocryst Pharmaceuticals stock.

You can see the complete history of Mr. Stonehouse stock trades at the bottom of the page.





Jon Stonehouse biography

Jon P. Stonehouse serves as President, Chief Executive Officer, Director of the Company. He joined BioCryst in January 2007 as Chief Executive Officer and Director. He was also named President in July 2007. Prior to joining the Company, he served as Senior Vice President of Corporate Development for Merck KGaA, a pharmaceutical company, since July 2002. His responsibilities included corporate mergers and aquisitions, global licensing and business development, corporate strategy and alliance management. Prior to joining Merck KGaA, Mr. Stonehouse held a variety of roles at Astra Merck/AstraZeneca. Mr. Stonehouse began his career in the pharmaceutical industry as a sales representative and held increasing sales leadership positions at Merck &Co., Inc. In 2008 and 2011, respectively, Mr. Stonehouse joined the Advisory Boards of Precision Biosciences, Inc., a private biotechnology company and Genscript, a private bioservices company. Also in December 2014, he joined the Board of Directors of Bellicum Pharmaceuticals, Inc., a publicly traded clinical stage biopharmaceutical company focused on novel cellular immunotherapies. Mr. Stonehouse earned his BS in Microbiology at the University of Minnesota. As Chief Executive Officer and President of BioCryst, Mr. Stonehouse brings to the Board an intimate knowledge of our business, and his executive experience in a variety of capacities at major pharmaceutical companies provides industry-specific operational experience that is beneficial to the Board.

What is the salary of Jon Stonehouse?

As the President, Chief Executive Officer y Director of Biocryst Pharmaceuticals, the total compensation of Jon Stonehouse at Biocryst Pharmaceuticals is $2,284,300. There are no executives at Biocryst Pharmaceuticals getting paid more.



How old is Jon Stonehouse?

Jon Stonehouse is 59, he's been the President, Chief Executive Officer y Director of Biocryst Pharmaceuticals since 2007. There are 10 older and 11 younger executives at Biocryst Pharmaceuticals. The oldest executive at Biocryst Pharmaceuticals Inc. is Robert Ingram, 77, who is the Independent Chairman of the Board.

What's Jon Stonehouse's mailing address?

Jon's mailing address filed with the SEC is 4505 EMPEROR BLVD., SUITE 200, DURHAM, NC, 27703.

Insiders trading at Biocryst Pharmaceuticals

Over the last 24 years, insiders at Biocryst Pharmaceuticals have traded over $76,362,383 worth of Biocryst Pharmaceuticals stock and bought 4,042,003 units worth $20,848,654 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Brothers Life Sciences Capi... y Carl L Gordon. On average, Biocryst Pharmaceuticals executives and independent directors trade stock every 31 days with the average trade being worth of $542,329. The most recent stock trade was executed by Amy E Mc Kee on 24 June 2024, trading 8,600 units of BCRX stock currently worth $54,352.



What does Biocryst Pharmaceuticals do?

biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.



Complete history of Mr. Stonehouse stock trades at Bellicum Pharmaceuticals Inc y Biocryst Pharmaceuticals

Persona
Trans.
Transacción
Precio total
Jon P Stonehouse
Presidente y CEO
Comprar $166,500
13 May 2024
Jon P Stonehouse
Presidente y CEO
Uso de opción $99,997
21 Mar 2023
Jon P Stonehouse
Presidente y CEO
Uso de opción $545,000
1 Feb 2023
Jon P Stonehouse
Presidente y CEO
Venta $153,690
15 Dec 2022
Jon P Stonehouse
Presidente y CEO
Uso de opción $422,554
1 Dec 2022
Jon P Stonehouse
Presidente y CEO
Uso de opción $870,320
11 Jan 2022
Jon P Stonehouse
Presidente y CEO
Uso de opción $557,254
15 Dec 2020
Jon P Stonehouse
Presidente y CEO
Comprar $72,500
18 Nov 2019
Jon P Stonehouse
Presidente y CEO
Uso de opción $96,000
3 Dec 2018
Jon P Stonehouse
Presidente y CEO
Uso de opción $100,006
17 May 2018
Jon P Stonehouse
Presidente y CEO
Uso de opción $185,654
28 Feb 2018
Jon P Stonehouse
Presidente y CEO
Uso de opción $99,998
20 Jan 2016
Jon P Stonehouse
Presidente y CEO
Uso de opción $399,981
15 Jul 2015
Jon P Stonehouse
Presidente y CEO
Uso de opción $24,000
19 Jun 2015
Jon P Stonehouse
Presidente y CEO
Uso de opción $232,802
9 May 2014
Jon P Stonehouse
Presidente y CEO
Uso de opción $215,520
23 May 2013
Jon P Stonehouse
Presidente y CEO
Venta $13,006
1 Mar 2012
Jon P Stonehouse
Presidente y CEO
Comprar $25,200
8 Aug 2011
Jon P Stonehouse
Presidente y CEO
Comprar $34,000
18 Mar 2011
Jon P Stonehouse
Presidente y CEO
Comprar $4,860
30 Jan 2009
Jon P Stonehouse
Presidente y CEO
Comprar $81,400
1 Dec 2008
Jon P Stonehouse
Presidente y CEO
Comprar $43,750
3 Nov 2008
Jon P Stonehouse
Presidente y CEO
Comprar $7,130
12 Aug 2008
Jon P Stonehouse
Presidente y CEO
Comprar $22,715
11 Aug 2008
Jon P Stonehouse
Presidente y CEO
Comprar $677
4 Aug 2008
Jon P Stonehouse
Presidente y CEO
Comprar $10,500
31 Jan 2008
Jon P Stonehouse
Presidente y CEO
Comprar $98,010
13 Aug 2007
Jon P Stonehouse
Presidente y CEO
Comprar $17,389
31 Jul 2007
Jon P Stonehouse
Director
Uso de opción $100,805
3 Jan 2023
Jon P Stonehouse
Director
Uso de opción $68,455
1 Sep 2022
Jon P Stonehouse
Director
Uso de opción $32,901
4 Jan 2022
Jon P Stonehouse
Director
Comprar $45,600
9 Nov 2018


Biocryst Pharmaceuticals executives and stock owners

Biocryst Pharmaceuticals executives and other stock owners filed with the SEC include: